Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

134.74USD
23 May 2017
Change (% chg)

-- (--)
Prev Close
$134.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
353,296
52-wk High
$137.00
52-wk Low
$95.14

Latest Key Developments (Source: Significant Developments)

Abiomed Q4 gaap earnings per share $0.33
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Abiomed Inc :Abiomed announces Q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year.Q4 gaap earnings per share $0.33.Q4 revenue $124.7 million versus i/b/e/s view $122.5 million.Q4 earnings per share view $0.35 -- Thomson Reuters I/B/E/S.Sees fy 2018 revenue up 25 to 29 percent.Sees fy 2018 revenue $555 million to $575 million.Fy2018 revenue view $574.3 million -- Thomson Reuters I/B/E/S.Fiscal year 2018 guidance for gaap operating margin to be in range of 22% to 24%.  Full Article

Abiomed announces Q4 revenue of $124.7 million, up 33 pct
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Abiomed Inc :Abiomed announces q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year.Q4 gaap earnings per share $0.33.Q4 revenue $124.7 million versus i/b/e/s view $122.5 million.Sees fy 2018 revenue up 25 to 29 percent.Sees fy 2018 revenue $555 million to $575 million.Q4 earnings per share view $0.35 -- Thomson Reuters I/B/E/S.Sees fiscal year 2018 guidance for gaap operating margin to be in range of 22% to 24%..Fy2018 earnings per share view $1.78, revenue view $574.3 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Q3 earnings per share $0.34
Thursday, 26 Jan 2017 07:00am EST 

Abiomed Inc : Says increasing lower end of its fiscal year 2017 revenue guidance with new range of $440 million to $445 million . Fy2017 revenue view $443.9 million -- Thomson Reuters I/B/E/S . Abiomed Inc - projects revenue to be around $122 million for Q4 of fiscal 2017 . Q4 revenue view $124.7 million -- Thomson Reuters I/B/E/S . Abiomed inc - maintaining its fiscal year guidance for gaap operating margin in range of 18 pct to 20 pct . Abiomed announces q3 fy 2017 revenue of $114.7 million, up 34 pct over prior year . Q3 gaap earnings per share $0.34 . Q3 revenue $114.7 million versus I/B/E/S view $112.7 million . Q3 earnings per share view $0.29 -- Thomson Reuters I/B/E/S .Sees Q4 2017 revenue about $122 million.  Full Article

Abiomed Q3 GAAP earnings per share $0.34
Thursday, 26 Jan 2017 07:00am EST 

Abiomed Inc : Abiomed announces Q3 FY 2017 revenue of $114.7 million, up 34% over prior year . Q3 GAAP earnings per share $0.34 . Q3 revenue $114.7 million versus I/B/E/S view $112.7 million . Q3 earnings per share view $0.29 -- Thomson Reuters I/B/E/S . Sees Q4 2017 revenue about $122 million . Increasing lower end of fiscal year 2017 revenue guidance with new range of $440 million to $445 million . Maintaining its fiscal year guidance for GAAP operating margin in range of 18% to 20% .FY2017 revenue view $443.9 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed announces 34 pct rise in preliminary Q3 revenue of $114.7 mln
Monday, 9 Jan 2017 04:01pm EST 

Abiomed Inc - : Abiomed announces preliminary Q3 FY 2017 revenue of $114.7 million, up 34% over prior year . Sees FY 2017 revenue $435 million to $445 million . Q3 revenue $114.7 million versus I/B/E/S view $113.4 million . Abiomed Inc says preliminary unaudited U.S. revenue from Impella products for Q3 grew 34% to approximately $100.3 million from $75.0 million in prior fiscal year . Abiomed Inc says for Q3 of fiscal 2017, U.S. patient usage grew 32% in comparison with same period of fiscal 2016 . Fy2017 earnings per share view $1.13, revenue view $444.7 million -- Thomson Reuters I/B/E/S .Q3 earnings per share view $0.29, revenue view $113.4 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed announces preliminary q3 preliminary revenue
Monday, 9 Jan 2017 04:01pm EST 

Abiomed Inc : Abiomed announces preliminary q3 fy 2017 revenue of $114.7 million, up 34% over prior year . Q3 revenue $114.7 million versus i/b/e/s view $113.4 million . Sees fy 2017 revenue $435 million to $445 million . Abiomed Inc - is maintaining its fiscal year 2017 revenue guidance of $435 million to $445 million . Abiomed Inc - also maintaining its fiscal year guidance for gaap operating margin to be in range of 18% to 20% .Abiomed Inc - qtrly preliminary unaudited u.s. Revenue from impella products grew 34% to approximately $100.3 million.  Full Article

Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc :Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures
Wednesday, 7 Dec 2016 07:00am EST 

Abiomed Inc : Has expanded FDA pre-market approval for impella heart pump use in PCI to include impella cp heart pump .Abiomed impella cp receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures.  Full Article

Abiomed reports Q2 FY 2017 gaap earnings per share $0.20
Thursday, 27 Oct 2016 07:00am EDT 

Abiomed Inc : Announces Q2 FY 2017 revenue of $103 million, up 35% over prior year . Q2 gaap earnings per share $0.20 . Q2 revenue $103 million versus I/B/E/S view $103.2 million . Sees FY 2017 revenue $435 million to $445 million . Q2 earnings per share view $0.24 -- Thomson Reuters I/B/E/S . Says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .FY 2017 revenue view $446.3 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study
Thursday, 27 Oct 2016 07:00am EDT 

Abiomed Inc : Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study . Says gets U.S. FDA approval of prospective feasibility study to evaluate use of Impella CP heart pump for unloading of left ventricle prior to primary percutaneous coronary intervention . Says trial will focus on feasibility and safety, and lay groundwork for a future trial .Says up to 50 patients at 10 sites will be included in study, which is expected to initiate in first half of calendar 2017.  Full Article

More From Around the Web

BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study

* Abiomed - enrollment of first patient in fda approved prospective feasibility study, STEMI door to unloading with Impella CP system in acute myocardial infarction